Xcell Therapeutics

About Xcell Therapeutics

Xcell Therapeutics, founded in Seoul, South Korea in 2015, is a public company specializing in the development and manufacturing of cell culture media for the regenerative medicine industry. The company was established with a focus on ethical science and, after a decade of research, developed its flagship product, CellCor™, a serum-free, chemically defined (CD) media. CellCor™ is composed of over 200 known compounds and is free from animal or plant-derived components, which addresses the ethical and technical limitations of traditional cell culture media.

The company's core technology platform, XPorT, is used to develop optimal, customized media for a wide variety of cells, including mesenchymal stem cells (MSCs), dermal papilla cells, keratinocytes, and immune cells (T/NK cells). Xcell Therapeutics serves biotechnology and pharmaceutical clients engaged in cell and gene therapy (CGT) research and production. Its business model involves the direct sale of its CellCor™ products and aims to expand through partnerships with contract development and manufacturing organizations (CDMOs) and white-label agreements. The company operates a GMP-certified production facility in Yongin with an annual capacity of 100,000 liters and has received FDA 510(k) listing for the facility.

Since its inception, Xcell Therapeutics has secured significant funding, including a Series C round that brought its cumulative investment to KRW 33.7 billion. Key investors include Korea Investment Partners, Industrial Bank of Korea, and SBI Investment. The company completed its IPO on the KOSDAQ exchange and is focused on global expansion, with plans to increase its distribution network to 30 countries. Led by CEO Lee Yi-il, Xcell Therapeutics aims to become a leading manufacturer in the global regenerative medicine market.